Sionna Therapeutics (SION) Pulls Back On CF Hopes With Valuation Still In FocusSimplywall·Jul 21 at 12:13 AMSION+2.58%
Sionna Therapeutics, Inc. (SION) Receives a Rating Update from a Top AnalystTip Ranks·Jul 20 at 08:15 AMSION+2.58%
5 Undervalued Stocks That Soared: SION +277%, FBRX +306%, NKTR +869% & Morerttnews·Jul 19 at 12:05 PMAMRX+3.70%PSNL-0.83%
Sionna Therapeutics (NASDAQ:SION) Hits New 12-Month High - Should You Buy?Market Beat·Jul 18 at 03:20 AMSION+2.58%BAC+0.79%
OrbiMed Advisors disposes of 85,918 Sionna Therapeutics shares worth $3.85 millionPUBT·Jul 9 at 03:44 PMSION+2.58%
Sionna Therapeutics Chief Legal Officer Jennifer Fitzpatrick disposes of 10,250 common shares worth $446,862.08PUBT·Jul 7 at 03:38 PMSION+2.58%
OrbiMed Advisors disposes of 115,844 Sionna Therapeutics shares worth $5.27 millionPUBT·Jul 2 at 03:43 PMSION+2.58%
Sionna Therapeutics shareholders elect Class II directors at annual meetingPUBT·Jun 18 at 03:06 PMSION+2.58%
LifeSci Capital Reaffirms Their Buy Rating on Sionna Therapeutics, Inc. (SION)Tip Ranks·May 16 at 09:35 AMSION+2.58%
RBC Capital Sticks to Its Sell Rating for Sionna Therapeutics, Inc. (SION)Tip Ranks·May 13 at 08:47 PMSION+2.58%
Yazdi Reiterates Buy on Sionna, Keeps $58 Price Target Ahead of High-Impact 2026 SION-719 ReadoutTip Ranks·May 13 at 05:05 AMSION+2.58%
Sionna Therapeutics (NASDAQ:SION) Stock Price Down 10.4% on Disappointing EarningsMarket Beat·May 12 at 01:54 PMSION+2.58%
Sionna Therapeutics shares are trading lower after the company reported worse-than-expected Q1 EPS results.benzinga_article·May 12 at 10:17 AMSION+2.58%
